Chagas disease reactivation after autologous stem cell transplant. Case report and literature review

Juan David Rojas, Mario Pereira , Bibiana Martínez , Julio César Gómez , Sonia Isabel Cuervo , .

Keywords: Trypanosoma cruzi, Chagas disease, multiple myeloma, hematopoietic stem cell transplantation, febrile neutropenia, parasitic diseases, immunosuppression

Abstract

Introduction: Chagas disease is an endemic parasitic infection in Latin America transmitted by triatomines. It is associated with risk factors such as poverty and rurality. After acute infection, a third of patients will present target organ involvement (heart, digestive tract, central nervous system). The remaining two thirds remain asymptomatic throughout their life. Pharmacological immunosuppression breaks the balance between the immune system and the parasite, favoring its reactivation.
Clinical case: We present the case of a 58-year-old man from a Colombian rural area with a diagnosis of multiple myeloma refractory to the first line of treatment who required a new chemotherapy scheme and consolidation with autologous stem cell transplant. During the post-transplant period, he suffered from febrile neutropenia. Initial microbiological studies were negative but the peripheral blood smear evidenced trypomastigotes in blood. With a diagnosis of acute Chagas disease in a post-transplant patient, benznidazole was started. The evolution of the patient was satisfactory.
Conclusions: Positive serology prior to transplantation makes it necessary to rule out reactivation of the pathology in the setting of febrile neutropenia. More studies are required to determine tools for estimating the probability of reactivation of the disease and defining the best cost-risk-benefit relation for the prophylactic therapy.

Downloads

Download data is not yet available.
  • Juan David Rojas Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia https://orcid.org/0000-0002-2694-2712
  • Mario Pereira Grupo de Trasplante de Precursores Hematopoyéticos, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia https://orcid.org/0000-0003-1539-1748
  • Bibiana Martínez Grupo de Patología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia https://orcid.org/0000-0002-8985-8462
  • Julio César Gómez Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia; Grupo de Infectología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia https://orcid.org/0000-0001-5841-1409
  • Sonia Isabel Cuervo Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia; Grupo de Investigación en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicas, Bogotá, D.C., Colombia; Grupo de Infectología, Instituto Nacional de Cancerología E.S.E., Bogotá, D.C., Colombia https://orcid.org/0000-0001-5676-880X

References

Rueda K, Trujillo JE, Carranza JC, Vallejo GA. Transmisión oral de Trypanosoma cruzi: una nueva situación epidemiológica de la enfermedad de Chagas en Colombia y otros países suramericanos. Biomédica. 2014;34:631-72. https://doi.org/10.7705/biomedica.v34i4.2204

World Health Organization. Chagas disease in Latin America: An epidemiological update based on 2010 estimates. Fecha de consulta: 5 de julio de 2021. Disponible en: https://www.who.int/wer/2015/wer9006.pdf?ua=1

Pereiro AC. Guidelines for the diagnosis and treatment of Chagas disease. Lancet. 2019;393:1486-7. https://doi.org/10.1016/S0140-6736(19)30288-0

Pierrotti LC, Carvalho NB, Amorin JP, Pascual J, Kotton CN, López-Vélez R. Chagas disease recommendations for solid-organ transplant recipients and donors. Transplantation 2018;102:S1-7. https://doi.org/10.1097/TP.0000000000002019

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:548-67. https://doi.org/10.1002/ajh.25791

Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 Trial. Blood. 2020;136:39. https://doi.org/10.1182/blood-2020-134538

Pérez CJ, Lymbery AJ, Thompson RCA. Reactivation of Chagas disease: Implications for global health. Trends Parasitol. 2015;31:595-603. https://doi.org/10.1016/j.pt.2015.06.006

Jarque I, Salavert M, Pemán J. Parasitic infections in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8:e2016035. https://doi.org/10.4084/MJHID.2016.035

Pinazo MJ, Espinosa G, Cortés-Lletget C, Posada EJ, Aldasoro E, Oliveira I, et al. Immunosuppression and Chagas disease: A management challenge. PLoS Negl Trop Dis 2013;7;e1965. https://doi.org/10.1371/journal.pntd.0001965

Riganti J, Maqueda MG, Piñero MCB, Volonteri VI, Galimberti RL. Reactivation of Chagas’ disease: Cutaneous manifestations in two immunosuppressed patients. Int J Dermatol. 2012;51:829-34. https://doi.org/10.1111/j.1365-4632.2011.05224.x

Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Fecha de consulta: 5 de julio de 2021. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/49653/9789275120439_eng.pdf

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009;15:1143-238. https://doi.org/10.1016/j.bbmt.2009.06.019

Dictar M, Sinagra A, Verón MT, Luna C, Dengra C, De Rissio A, et al. Recipients and donors of bone marrow transplants suffering from Chagas’ disease: Management and preemptive therapy of parasitemia. Bone Marrow Transplant. 1998;21:391-3. https://doi.org/10.1038/sj.bmt.1701107

Altclas J, Sinagra A, Jaimovich G, Salgueira C, Luna C, Requejo A, et al. Reactivation of chronic Chagas’ disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole. Transpl Infect Dis. 1999;1:135-7. https://doi.org/10.1034/j.1399-3062.1999.010207.x

Altclas J, Sinagra A, Dictar M, Luna C, Verón MT, De Rissio AM, et al. Chagas disease in bone marrow transplantation: An approach to preemptive therapy. Bone Marrow Transplant. 2005;36:123-9. https://doi.org/10.1038/sj.bmt.1705006

Chalela CM, Peña AM, Roa AM, Reyes DL, Rueda JP, Salazar LA, et al. Reactivation of chagas disease after autologous hematopoietic stem cell transplantation. Rev Soc Bras Med Trop. 2021;54:1-4. https://doi.org/10.1590/0037-8682-0143-2020

Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: Common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis. 2009;9:324-30. https://10.1016/S1473-3099(09)70088-X

How to Cite
1.
Rojas JD, Pereira M, Martínez B, Gómez JC, Cuervo SI. Chagas disease reactivation after autologous stem cell transplant. Case report and literature review. biomedica [Internet]. 2022 Jun. 1 [cited 2024 May 11];42(2):224-33. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/6288

Some similar items:

Published
2022-06-01
Section
Case presentation

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code